You are here: Industry Insights > Pertuzumab

News List

Next Stop for PD-1? MNC for Subcutaneous Preparation Takes the Lead in Competition, Leading to A More Fierce Domestic Conpetition, but Differentiation is not easy Spur 203/PharmaSources
December 14, 2023
The competition for the subcutaneous formulation of PD-1/PD-L1 inhibitors has been spreading globally for a long time, with Roche and Bristol Myers Squibb currently leading the pack.
FDA Approves Home-Administered Breast Cancer Treatment americanpharmaceuticalreview
July 09, 2020
The U.S. Food and Drug Administration (FDA) has approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer.
FDA Approves Pertuzumab, Trastuzumab, Hyaluronidase-zzxf Combination americanpharmaceuticalreview
July 01, 2020
The Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf (PHESGO, Genentech) for subcutaneous injection.
Two Drugs Make Inroads Against Aggressive Breast Cancers drugs
December 12, 2019
Two experimental drugs show real promise against an aggressive, treatment-resistant form of breast cancer that's spread to other parts of the body, researchers say.
Pertuzumab, Trastuzumab Combination with ENHANZE Drug Delivery Meets Primary Endpoint americanpharmaceuticalreview
September 17, 2019
Halozyme announced the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.
NICE recommends Roche’s breast cancer drug pertuzumab pharmaceutical-technology
February 19, 2019
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Roche’s Perjeta (pertuzumab) by the National Health Service (NHS) to treat early HER2-positive breast cancer, which has spread to lymph nodes.....
SMC accepts four medicines for NHS use pharmatimes
December 11, 2018
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.